Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management
Authors
Keywords
-
Journal
Neurotherapeutics
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-04-05
DOI
10.1007/s13311-022-01224-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
- (2022) Gabriel Bsteh et al. EUROPEAN JOURNAL OF NEUROLOGY
- B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
- (2022) Marco Iannetta et al. Frontiers in Immunology
- Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry
- (2021) Michael Guger et al. JOURNAL OF NEUROLOGY
- Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
- (2021) Arpan Patel et al. JAMA Neurology
- Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study
- (2021) Javier Riancho et al. Frontiers in Immunology
- Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
- (2021) Guerrieri S. et al. JOURNAL OF NEUROLOGY
- Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
- (2021) Stephen L Hauser et al. NEUROLOGY
- Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis
- (2021) Giulio Disanto et al. JAMA Neurology
- Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab
- (2021) Livnat Brill et al. JAMA Neurology
- Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia
- (2021) Mohammed Al Jumah et al. Multiple Sclerosis and Related Disorders
- Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
- (2021) Leoni Rolfes et al. Neurology-Neuroimmunology & Neuroinflammation
- Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
- (2021) Matthias B Moor et al. Lancet Rheumatology
- Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
- (2021) Anat Achiron et al. JOURNAL OF NEUROIMMUNOLOGY
- Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
- (2021) Alasdair J Coles et al. Multiple Sclerosis Journal
- Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis
- (2021) Frederik Novak et al. Multiple Sclerosis and Related Disorders
- Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
- (2021) Jose M. Serra López-Matencio et al. Frontiers in Neurology
- Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
- (2021) Lutz Achtnichts et al. Vaccines
- Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients
- (2020) Peter Alping et al. ANNALS OF NEUROLOGY
- Pharmacodynamics of natalizumab extended interval dosing in MS
- (2020) Lana Zhovtis Ryerson et al. Neurology-Neuroimmunology & Neuroinflammation
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
- (2020) Anna He et al. LANCET NEUROLOGY
- A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
- (2020) Edward Fox et al. Multiple Sclerosis Journal
- Alemtuzumab: Rare serious adverse events of a high-efficacy drug
- (2020) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder
- (2020) Andrea Ines Ciplea et al. Neurology-Neuroimmunology & Neuroinflammation
- Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases
- (2020) Sara C. LaHue et al. Neurology-Neuroimmunology & Neuroinflammation
- Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
- (2020) Tjalf Ziemssen et al. CNS DRUGS
- Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
- (2020) Stephen L. Hauser et al. NEUROLOGY
- Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study
- (2020) Amit Bar-Or et al. NEUROLOGY
- Ofatumumab versus Teriflunomide in Multiple Sclerosis
- (2020) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years
- (2020) Jiwon Oh et al. Multiple Sclerosis and Related Disorders
- Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
- (2020) Michael Guger et al. Frontiers in Neurology
- Ocrelizumab shorter infusion
- (2020) Hans-Peter Hartung Neurology-Neuroimmunology & Neuroinflammation
- Mitigating alemtuzumab-associated autoimmunity in MS
- (2020) Ethan Meltzer et al. Neurology-Neuroimmunology & Neuroinflammation
- Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review
- (2020) Huah Shin Ng et al. Expert Opinion On Drug Safety
- Modeling the Efficacy of Natalizumab in Multiple Sclerosis Patients Who Switch From Every‐4‐Week Dosing to Extended‐Interval Dosing
- (2020) Ih Chang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
- (2020) Imtiaz A Samjoo et al. Journal of Comparative Effectiveness Research
- Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing
- (2019) John F. Foley et al. Multiple Sclerosis and Related Disorders
- Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
- (2019) Adam Cuker et al. Multiple Sclerosis Journal
- Long-Term Stability of Neuroaxonal Structure in Alemtuzumab-Treated Relapsing–Remitting Multiple Sclerosis Patients
- (2019) Jillian K. Chan et al. JOURNAL OF NEURO-OPHTHALMOLOGY
- Highly active multiple sclerosis: An update
- (2019) Cindy Díaz et al. Multiple Sclerosis and Related Disorders
- Considerations for the Design of Antibody-Based Therapeutics
- (2019) Dennis R. Goulet et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab
- (2019) J William L Brown et al. Multiple Sclerosis Journal
- Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
- (2019) Kevin O. Saunders Frontiers in Immunology
- Emerging safety issues in alemtuzumab-treated MS patients
- (2019) Joep Killestein et al. Multiple Sclerosis Journal
- Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
- (2019) Marinella Clerico et al. Neurotherapeutics
- Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies
- (2019) Danielle J. Smalls et al. PHARMACOTHERAPY
- Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
- (2019) Kristen M. Krysko et al. Neurology-Neuroimmunology & Neuroinflammation
- B-cell Therapy for Multiple Sclerosis: Entering an era
- (2018) Ariele L. Greenfield et al. ANNALS OF NEUROLOGY
- Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy
- (2018) H. K. Olberg et al. EUROPEAN JOURNAL OF NEUROLOGY
- ‘No evidence of disease activity’ - is it an appropriate surrogate in multiple sclerosis?
- (2018) H. Hegen et al. EUROPEAN JOURNAL OF NEUROLOGY
- Alemtuzumab for the treatment of multiple sclerosis
- (2018) Jennifer R. Evan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
- (2018) Antonio Riccardo Buonomo et al. Expert Opinion On Drug Safety
- Ublituximab for the treatment of CD20 positive B-cell malignancies
- (2018) Hani M. Babiker et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
- (2018) E. C. Tallantyre et al. JOURNAL OF NEUROLOGY
- Multiple sclerosis
- (2018) Alan J Thompson et al. LANCET
- Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
- (2018) Yasuo Oshima et al. Multiple Sclerosis Journal
- A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab
- (2018) Irene M Vavasour et al. Multiple Sclerosis Journal
- Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab
- (2018) Benoit Meunier et al. Multiple Sclerosis Journal
- Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis
- (2018) Thomas Wehrum et al. NEUROLOGY
- Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
- (2018) Mika Saarela et al. NEUROLOGY
- Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance
- (2018) Paolo A. Muraro et al. NEUROLOGY
- Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab
- (2018) Sherry Masoud et al. RHEUMATOLOGY
- Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients
- (2018) Yasuo Oshima et al. Multiple Sclerosis Journal
- A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab
- (2018) Irene M Vavasour et al. Multiple Sclerosis Journal
- Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab
- (2018) Benoit Meunier et al. Multiple Sclerosis Journal
- Severe neutropenia after rituximab-treatment of multiple sclerosis
- (2018) Eero Rissanen et al. Multiple Sclerosis and Related Disorders
- Efficacy and safety of natalizumab extended interval dosing
- (2018) Bassem I. Yamout et al. Multiple Sclerosis and Related Disorders
- Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis
- (2018) L.J.W. Canham et al. Multiple Sclerosis and Related Disorders
- Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies
- (2018) Christoph Metze et al. CNS Neuroscience & Therapeutics
- Infusion-related reactions to rituximab: frequency, mechanisms and predictors
- (2018) Franciane Paul et al. Expert Review of Clinical Immunology
- Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
- (2018) Sibyl Wray et al. Multiple Sclerosis Journal
- Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria
- (2018) Gabriel Bsteh et al. Multiple Sclerosis Journal
- Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment
- (2018) Jonas Graf et al. Multiple Sclerosis Journal
- Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
- (2018) Stefan Gingele et al. Cells
- Management of Demyelinating Disorders in Pregnancy
- (2018) Tamara B. Kaplan NEUROLOGIC CLINICS
- Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
- (2017) Kumar Kandadi Muralidharan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and safety of rituximab in neuromyelitis optica: Review of evidence
- (2017) Omid Mirmosayyeb et al. Journal of Research in Medical Sciences
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
- (2017) Aiden Haghikia et al. LANCET NEUROLOGY
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Rituximab treatment of myasthenia gravis: A systematic review
- (2017) Rup Tandan et al. MUSCLE & NERVE
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Alemtuzumab CARE-MS II 5-year follow-up
- (2017) Alasdair J. Coles et al. NEUROLOGY
- Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab
- (2017) Joshua Barton et al. NEUROLOGY
- Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis
- (2017) Jeffrey M. Gelfand et al. Neurotherapeutics
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low level of Rituximab in human breast milk in a patient treated during lactation
- (2017) Yngvill Bragnes et al. RHEUMATOLOGY
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab
- (2017) Marinella Clerico et al. Multiple Sclerosis Journal
- Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome
- (2017) Wallace J Brownlee et al. Multiple Sclerosis Journal
- Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis
- (2017) Saša Šega-Jazbec et al. Multiple Sclerosis and Related Disorders
- Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
- (2017) Cristina Guarnera et al. Therapeutics and Clinical Risk Management
- Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
- (2017) Eva Havrdova et al. Therapeutics and Clinical Risk Management
- Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response
- (2017) Mario Rotondi et al. Frontiers in Endocrinology
- Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
- (2016) Susan Friend et al. BMC Neurology
- Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
- (2016) Jeff P. Sharman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis
- (2016) JL Orthmann-Murphy et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
- (2016) Thomas Berger et al. CNS DRUGS
- Targeting B cells in treatment of autoimmunity
- (2016) S Elizabeth Franks et al. CURRENT OPINION IN IMMUNOLOGY
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis
- (2016) María Rosario Blasco et al. JOURNAL OF NEUROLOGY
- Extended interval dosing of natalizumab in multiple sclerosis
- (2016) L Zhovtis Ryerson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS
- (2016) Steffen Pfeuffer et al. NEUROLOGY
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
- (2016) Douglas L. Arnold et al. NEUROLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Disease activity return after natalizumab cessation in multiple sclerosis
- (2016) Maria Rasenack et al. Expert Review of Neurotherapeutics
- Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
- (2016) MD Willis et al. Multiple Sclerosis Journal
- Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management
- (2015) Moeber Mahzari et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Classification, diagnosis, and differential diagnosis of multiple sclerosis
- (2015) Ilana Katz Sand CURRENT OPINION IN NEUROLOGY
- Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
- (2015) Daniela Rau et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs
- (2014) E. Portaccio et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis
- (2014) Michael Kaufman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- The global burden of listeriosis: a systematic review and meta-analysis
- (2014) Charline Maertens de Noordhout et al. LANCET INFECTIOUS DISEASES
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity
- (2014) O. Kousin-Ezewu et al. NEUROLOGY
- Natalizumab Use During the Third Trimester of Pregnancy
- (2014) Aiden Haghikia et al. JAMA Neurology
- FDA: Increased HBV Reactivation Risk With Ofatumumab or Rituximab
- (2013) Mike Mitka JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing-Remitting Multiple Sclerosis
- (2013) X. Zhang et al. JOURNAL OF IMMUNOLOGY
- Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
- (2013) M Le Garff-Tavernier et al. LEUKEMIA
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Immune competence after alemtuzumab treatment of multiple sclerosis
- (2013) C. L. McCarthy et al. NEUROLOGY
- Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation
- (2013) J. L. Jones et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rituximab for the treatment of rheumatoid arthritis: an update
- (2013) Chi Chiu Mok Drug Design Development and Therapy
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab
- (2012) T. Button et al. Multiple Sclerosis Journal
- Humoral immune response to influenza vaccine in natalizumab-treated MS patients
- (2012) Mattias Vågberg et al. NEUROLOGICAL RESEARCH
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
- (2011) A. Cuker et al. BLOOD
- Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
- (2011) Grant A Hill-Cawthorne et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
- (2011) J Theodore Phillips et al. Multiple Sclerosis Journal
- Immune reconstitution inflammatory syndrome in natalizumab-associated PML
- (2011) I. L. Tan et al. NEUROLOGY
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
- (2010) J.-E. Gottenberg et al. ARTHRITIS AND RHEUMATISM
- Pregnancy outcomes after maternal exposure to rituximab
- (2010) E. F. Chakravarty et al. BLOOD
- CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment
- (2010) Giovanni Frisullo et al. Multiple Sclerosis Journal
- The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases
- (2010) Valeria Bruno et al. NEUROLOGICAL SCIENCES
- Hepatitis B Reactivation and Rituximab in the Oncology Practice
- (2010) J. Villadolid et al. ONCOLOGIST
- Developmental Immunotoxicology Assessment of Rituximab in Cynomolgus Monkeys
- (2010) Anu Vaidyanathan et al. TOXICOLOGICAL SCIENCES
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial
- (2009) Clifton O. Bingham et al. ARTHRITIS AND RHEUMATISM
- Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor
- (2009) Nancy G. Wehner et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Effects of natalizumab, an α4 integrin inhibitor, on fertility in male and female guinea pigs
- (2009) Nancy G. Wehner et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an α4 integrin inhibitor
- (2009) Nancy G. Wehner et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Receptor-mediated uptake and transport of macromolecules in the human placenta
- (2009) Henning Schneider et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- (2009) B. O. Khatri et al. NEUROLOGY
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Rituximab Administration in Third Trimester of Pregnancy Suppresses Neonatal B-Cell Development
- (2008) D. T. Klink et al. Clinical & Developmental Immunology
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started